Bioengineering coagulation factors for improved hemophilia treatments☆


The implementation of prophylaxis with regular factor VIII (FVIII) replacement for patients with hemophilia radically changed the clinical presentation of this condition, from a disease characterized by progressive disabling musculoskeletal complications, to one compatible with an active and virtually normal lifestyle. In Brazil, although most adults with… (More)
DOI: 10.1016/j.bjhh.2016.05.001


Cite this paper

@inproceedings{Hounkpe2016BioengineeringCF, title={Bioengineering coagulation factors for improved hemophilia treatments☆}, author={Bidossessi Wilfried Hounkpe and E V De Paula}, booktitle={Revista brasileira de hematologia e hemoterapia}, year={2016} }